What is the actual selling price range of a box of Vemurafenib in China?

Vemurafenib/zobovo(Vemurafenib)As an innovative BRAF inhibitor developed by Roche, it has been officially launched in mainland China and included in the medical insurance system. It is suitable for the treatment of BRAF detected by FDA-approved tests Patients with V600E-mutated unresectable or metastatic melanoma and Erdheim-Chester disease with BRAF V600 mutations. According to the latest drug catalog, the original research version with specifications of 240 mg × 56 tablets/box is priced at about RMB 5,000. However, due to regional differences and different medical insurance reimbursement ratios, the actual price paid by patients may be lower.

In overseas markets, the pricing of vemurafenib is slightly different. Taking the Turkish European version of Zelboraf as an example, drugs of the same specification cost about 3,000 yuan when converted into RMB. Price fluctuations are related to local drug price controls and exchange rate changes. In some Southeast Asian regions, such as Laos and other countries, versions produced through generic drugs have appeared. The ingredients of these generic drugs of vemurafenib are the same as the original drugs. They only differ in brand packaging and registration channels. Each box is sold for about 2,000 yuan, and the cost is significantly reduced.

It is worth noting that although overseas generic versions have obvious price advantages, not all channels meet the certification standards of the China Food and Drug Administration (NMPA). If patients obtain drugs through drug purchase platforms, they need to pay special attention to the source and authenticity verification of the drugs. Original drugs still have higher guarantees in terms of stability, purity and clinical verification.

With the inclusion of vemurafenib in medical insurance, its accessibility in China has significantly improved. After medical insurance reimbursement, the patient's out-of-pocket payment dropped by nearly 70% compared with the early import stage, greatly reducing the burden of long-term treatment. For long-term oral drugs, this adjustment in price policy is of great significance and also reflects the Chinese market's ability to respond quickly to innovative targeted drugs.

Reference: https://www.drugs.com/mtm/vemurafenib.html